The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways

Anti-TNF therapy, Crohn's disease, Immunogenicity, Inflammatory bowel diseases, Pharmacology, Ulcerative colitis
dx.doi.org/10.1016/j.crohns.2010.04.004, hdl.handle.net/1765/20276
Journal of Crohn's and Colitis
Article in press - dd August 2010
Erasmus MC: University Medical Center Rotterdam

Allez, M, Karmiris, K, Louis, E, van Assche, G, Ben-Horin, S, Klein, A, … Chowers, Y. (2010). Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis (Vol. 4, pp. 355–366). doi:10.1016/j.crohns.2010.04.004